Johnson & Johnson (NYSE: JNJ) today announced results from additional analyses of the Phase 2 DAHLIAS study highlighting improvement in key measures of disease activity and significant IgG reduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback